ArticleJournal of clinical medicine2019

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages.

Hao-Yu Chuang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.